We Are Challenging The Current Cancer Paradigm And Developing New Classes Of Anti-Cancer Metabolic Therapies

Traditionally cancer is thought to originate from random genetic mutations that differ on a case by case basis. This conventional view has shaped current cancer treatment protocols and has led to costly, resource intensive, personalized cancer therapies. But what if these mutations are symptoms instead of the underlying root cause of cancer?

What if cancer is not a genetic disease?

At Tieös, we view these genetic mutations as a downstream phenomenon with inciting upstream metabolic aberrations and we are challenging current conventions with this idea. We believe cancer is a metabolic disease. This is why nearly all cancers are diagnosed with a metabolic test -- a PET scan, as most cancers share common metabolic features.

Cancer cells DO NOT use oxygen to make energy

The majority of cancer cells are unique from normal cells in that they do not use oxygen to create energy or ATP. This distinction, known as the Warburg effect, is one of many metabolic properties unique to cancer cells. Because of this metabolic defect, cancer cells must use other pathways to create energy in order to survive. They use glucose, glutamine, lactate and other amino acids at a disproportional rate compared to normal cells to compensate for this energy production crisis.

Cancer cells use different metabolic pathways for energy production

 
 

Cancer cells use different metabolic pathways for energy production -- and this can be targeted. These cancer specific targets are present in the vast majority of cancers, regardless of tissue origin. Tieös plans to exploit these unique behaviours, as it represents an untapped opportunity for cancer therapeutics.

Tieös Is Developing New Treatments Which Target Metabolic Pathways Unique To Cancer Cells

Our Approach Has The Potential To Revolutionize Current Treatment Regimens

Tieös is creating novel classes of small molecule drugs to starve cancer cells of their energy and prevent cancer from proliferating. Using cutting edge computational biology and artificial intelligence algorithms, Tieös has developed compounds which will target multiple metabolic pathways simultaneously, while utilizing intelligent design elements to minimize drug resistance and collateral damage to healthy and vital cells.

The development of our pipeline of cancer therapies is focused on:

  • Extensive review of metabolic interactions specific to cancer cells
  • Novel use of proteomics, metabolomics and 3D in silico modelling
  • Proprietary analysis of cancer specific molecular/protein binding patterns
  • Targeted compound structural design; focused on minimizing toxicity
  • Utilization of expertise in biochemistry and medicinal chemistry, in a clinical context

 

Tieös’ vision is to tangibly improve PATIENT quality of life and TREATMENT outcomes

 

Core Team

arun2.png

Arun Anand

Co-Founder, Chief Executive Officer

Dr. Anand completed his MD at the University of Calgary and residency in Anesthesiology at the University of Ottawa. He has previously worked at General Electric Corporate Finance and has been involved in various other entrepreneurial ventures. He is presently one of Canada’s youngest specialist physicians.

 
andy.jpg

Andrew Roberts

Co-Founder, Chief scientific Officer

Dr. Roberts obtained dual degrees in evolutionary biology and public health while being a three-time all Canadian varsity athlete at the University of New Brunswick. He went on to complete his master’s degree in exercise physiology before pursuing medical school. He completed his Anesthesiology residency at the University of Ottawa, where he was the Chief Resident. He is currently department Chief of Anesthesiology at The Moncton Hospital and an Assistant Professor at both Dalhousie University and Université de Sherbrooke.

 
image007.png

Rishi Anand

Senior vice president, Head of Operations

Mr. Anand obtained his bachelor of applied science in electrical engineering from the University of Waterloo. He has held various management and technical roles in the semiconductor industry and has been a key architect in the design of several advanced digital signal processing algorithms. He has expertise in project management, operational planning and IT infrastructure deployment.

 
karina.jpg

Karina Ng

Senior vice president, Head of business development

Ms. Ng completed her MBA at INSEAD and bachelor of applied science in electrical engineering at the University of Waterloo. She has held various positions at McKinsey & Company and Barclays Capital. She is currently head of strategic planning at Sandoz, a division of Novartis, for the Asia-Pacific region. She has extensive management and technical experience in the pharmaceutical and healthcare sector.

 
 

Partnerships & Alliances

 
 
 

info@tieospharma.com

(647) 715-4513
(506) 804-1016